Yuexin Liu1, Maya Yasukawa2, Kexin Chen3, Limei Hu4, Russell R Broaddus4, Li Ding5, Elaine R Mardis5, Paul Spellman6, Douglas A Levine7, Gordon B Mills8, Ilya Shmulevich9, Anil K Sood10, Wei Zhang1. 1. Department of Pathology, University of Texas MD Anderson Cancer Center, Houston2Institute for Systems Biology/MD Anderson Cancer Center Genome Data Analysis Center, The Cancer Genome Atlas, Bethesda, Maryland. 2. Department of Pathology, University of Texas MD Anderson Cancer Center, Houston3Department of Obstetrics and Gynecology, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan. 3. Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Hospital and Institute, Tianjin, PR China. 4. Department of Pathology, University of Texas MD Anderson Cancer Center, Houston. 5. Genome Institute, Washington University, St Louis, Missouri. 6. Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland. 7. Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York. 8. Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston. 9. Institute for Systems Biology/MD Anderson Cancer Center Genome Data Analysis Center, The Cancer Genome Atlas, Bethesda, Maryland9Institute for Systems Biology, Seattle, Washington. 10. Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston11Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston.
Abstract
IMPORTANCE: Chemotherapy response in the majority of patients with ovarian cancer remains unpredictable. OBJECTIVE: To identify novel molecular markers for predicting chemotherapy response in patients with ovarian cancer. DESIGN, SETTING, AND PARTICIPANTS: Observational study of genomics and clinical data of high-grade serous ovarian cancer cases with genomic and clinical data made public between 2009 and 2014 via the Cancer Genome Atlas project. MAIN OUTCOMES AND MEASURES: Chemotherapy response (primary outcome) and overall survival (OS), progression-free survival (PFS), and platinum-free duration (secondary outcome). RESULTS: In 512 patients with ovarian cancer with available whole-exome sequencing data, mutations from 8 members of the ADAMTS family (ADAMTS mutations) with an overall mutation rate of approximately 10.4% were associated with a significantly higher chemotherapy sensitivity (100% for ADAMTS-mutated vs 64% for ADAMTS wild-type cases; P < .001) and longer platinum-free duration (median platinum-free duration, 21.7 months for ADAMTS-mutated vs 10.1 months for ADAMTS wild-type cases; P = .001). Moreover, ADAMTS mutations were associated with significantly better OS (hazard ratio [HR], 0.54 [95% CI, 0.42-0.89]; P = .01 and median OS, 58.0 months for ADAMTS-mutated vs 41.3 months for ADAMTS wild-type cases) and PFS (HR, 0.42 [95% CI, 0.38-0.70]; P < .001 and median PFS, 31.8 for ADAMTS-mutated vs 15.3 months for ADAMTS wild-type cases). After adjustment by BRCA1 or BRCA2 mutation, surgical stage, residual tumor, and patient age, ADAMTS mutations were significantly associated with better OS (HR, 0.53 [95% CI, 0.32-0.87]; P = .01), PFS (HR, 0.40 [95% CI, 0.25-0.62]; P < .001), and platinum-free survival (HR, 0.45 [95% CI, 0.28-0.73]; P = .001). ADAMTS-mutated cases exhibited a distinct mutation spectrum and were significantly associated with tumors with a higher genome-wide mutation rate than ADAMTS wild-type cases across the whole exome (median mutation number per sample, 121 for ADAMTS-mutated vs 69 for ADAMTS wild-type cases; P < .001). CONCLUSIONS AND RELEVANCE: ADAMTS mutations may contribute to outcomes in ovarian cancer cases without BRCA1 or BRCA2 mutations and may have important clinical implications.
IMPORTANCE: Chemotherapy response in the majority of patients with ovarian cancer remains unpredictable. OBJECTIVE: To identify novel molecular markers for predicting chemotherapy response in patients with ovarian cancer. DESIGN, SETTING, AND PARTICIPANTS: Observational study of genomics and clinical data of high-grade serous ovarian cancer cases with genomic and clinical data made public between 2009 and 2014 via the Cancer Genome Atlas project. MAIN OUTCOMES AND MEASURES: Chemotherapy response (primary outcome) and overall survival (OS), progression-free survival (PFS), and platinum-free duration (secondary outcome). RESULTS: In 512 patients with ovarian cancer with available whole-exome sequencing data, mutations from 8 members of the ADAMTS family (ADAMTS mutations) with an overall mutation rate of approximately 10.4% were associated with a significantly higher chemotherapy sensitivity (100% for ADAMTS-mutated vs 64% for ADAMTS wild-type cases; P < .001) and longer platinum-free duration (median platinum-free duration, 21.7 months for ADAMTS-mutated vs 10.1 months for ADAMTS wild-type cases; P = .001). Moreover, ADAMTS mutations were associated with significantly better OS (hazard ratio [HR], 0.54 [95% CI, 0.42-0.89]; P = .01 and median OS, 58.0 months for ADAMTS-mutated vs 41.3 months for ADAMTS wild-type cases) and PFS (HR, 0.42 [95% CI, 0.38-0.70]; P < .001 and median PFS, 31.8 for ADAMTS-mutated vs 15.3 months for ADAMTS wild-type cases). After adjustment by BRCA1 or BRCA2 mutation, surgical stage, residual tumor, and patient age, ADAMTS mutations were significantly associated with better OS (HR, 0.53 [95% CI, 0.32-0.87]; P = .01), PFS (HR, 0.40 [95% CI, 0.25-0.62]; P < .001), and platinum-free survival (HR, 0.45 [95% CI, 0.28-0.73]; P = .001). ADAMTS-mutated cases exhibited a distinct mutation spectrum and were significantly associated with tumors with a higher genome-wide mutation rate than ADAMTS wild-type cases across the whole exome (median mutation number per sample, 121 for ADAMTS-mutated vs 69 for ADAMTS wild-type cases; P < .001). CONCLUSIONS AND RELEVANCE: ADAMTS mutations may contribute to outcomes in ovarian cancer cases without BRCA1 or BRCA2 mutations and may have important clinical implications.
Authors: G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai Journal: Nature Date: 2001-10-04 Impact factor: 49.962
Authors: Lisa M Landrum; James Java; Cara A Mathews; Grainger S Lanneau; Larry J Copeland; Deborah K Armstrong; Joan L Walker Journal: Gynecol Oncol Date: 2013-04-08 Impact factor: 5.482
Authors: Estefanía Martino-Echarri; Rubén Fernández-Rodríguez; Francisco Javier Rodríguez-Baena; Antonio Barrientos-Durán; Antoni X Torres-Collado; María del Carmen Plaza-Calonge; Suyapa Amador-Cubero; Javier Cortés; Louise E Reynolds; Kairbaan M Hodivala-Dilke; Juan Carlos Rodríguez-Manzaneque Journal: Int J Cancer Date: 2013-06-13 Impact factor: 7.396
Authors: Ludmil B Alexandrov; Serena Nik-Zainal; David C Wedge; Samuel A J R Aparicio; Sam Behjati; Andrew V Biankin; Graham R Bignell; Niccolò Bolli; Ake Borg; Anne-Lise Børresen-Dale; Sandrine Boyault; Birgit Burkhardt; Adam P Butler; Carlos Caldas; Helen R Davies; Christine Desmedt; Roland Eils; Jórunn Erla Eyfjörd; John A Foekens; Mel Greaves; Fumie Hosoda; Barbara Hutter; Tomislav Ilicic; Sandrine Imbeaud; Marcin Imielinski; Marcin Imielinsk; Natalie Jäger; David T W Jones; David Jones; Stian Knappskog; Marcel Kool; Sunil R Lakhani; Carlos López-Otín; Sancha Martin; Nikhil C Munshi; Hiromi Nakamura; Paul A Northcott; Marina Pajic; Elli Papaemmanuil; Angelo Paradiso; John V Pearson; Xose S Puente; Keiran Raine; Manasa Ramakrishna; Andrea L Richardson; Julia Richter; Philip Rosenstiel; Matthias Schlesner; Ton N Schumacher; Paul N Span; Jon W Teague; Yasushi Totoki; Andrew N J Tutt; Rafael Valdés-Mas; Marit M van Buuren; Laura van 't Veer; Anne Vincent-Salomon; Nicola Waddell; Lucy R Yates; Jessica Zucman-Rossi; P Andrew Futreal; Ultan McDermott; Peter Lichter; Matthew Meyerson; Sean M Grimmond; Reiner Siebert; Elías Campo; Tatsuhiro Shibata; Stefan M Pfister; Peter J Campbell; Michael R Stratton Journal: Nature Date: 2013-08-14 Impact factor: 49.962
Authors: Cyriac Kandoth; Nikolaus Schultz; Andrew D Cherniack; Rehan Akbani; Yuexin Liu; Hui Shen; A Gordon Robertson; Itai Pashtan; Ronglai Shen; Christopher C Benz; Christina Yau; Peter W Laird; Li Ding; Wei Zhang; Gordon B Mills; Raju Kucherlapati; Elaine R Mardis; Douglas A Levine Journal: Nature Date: 2013-05-02 Impact factor: 49.962
Authors: Sharon A Savage; Lisa Mirabello; Zhaoming Wang; Julie M Gastier-Foster; Richard Gorlick; Chand Khanna; Adrienne M Flanagan; Roberto Tirabosco; Irene L Andrulis; Jay S Wunder; Nalan Gokgoz; Ana Patiño-Garcia; Luis Sierrasesúmaga; Fernando Lecanda; Nilgün Kurucu; Inci Ergurhan Ilhan; Neriman Sari; Massimo Serra; Claudia Hattinger; Piero Picci; Logan G Spector; Donald A Barkauskas; Neyssa Marina; Silvia Regina Caminada de Toledo; Antonio S Petrilli; Maria Fernanda Amary; Dina Halai; David M Thomas; Chester Douglass; Paul S Meltzer; Kevin Jacobs; Charles C Chung; Sonja I Berndt; Mark P Purdue; Neil E Caporaso; Margaret Tucker; Nathaniel Rothman; Maria Teresa Landi; Debra T Silverman; Peter Kraft; David J Hunter; Nuria Malats; Manolis Kogevinas; Sholom Wacholder; Rebecca Troisi; Lee Helman; Joseph F Fraumeni; Meredith Yeager; Robert N Hoover; Stephen J Chanock Journal: Nat Genet Date: 2013-06-02 Impact factor: 38.330
Authors: Josephine Walton; Julianna Blagih; Darren Ennis; Elaine Leung; Suzanne Dowson; Malcolm Farquharson; Laura A Tookman; Clare Orange; Dimitris Athineos; Susan Mason; David Stevenson; Karen Blyth; Douglas Strathdee; Frances R Balkwill; Karen Vousden; Michelle Lockley; Iain A McNeish Journal: Cancer Res Date: 2016-08-16 Impact factor: 12.701